Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
View ORCID ProfileNiveditha Ravindra, Laura W. Dillon, Gege Gui, Matthew Smith, Lukasz P. Gondek, Richard J. Jones, Adam Corner, View ORCID ProfileChristopher S. Hourigan, Alexander J. Ambinder
doi: https://doi.org/10.1101/2023.08.14.23294087
Niveditha Ravindra
1Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Laura W. Dillon
1Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Gege Gui
1Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Matthew Smith
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Lukasz P. Gondek
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Richard J. Jones
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
Adam Corner
3Bio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA
Christopher S. Hourigan
1Laboratory of Myeloid Malignancies, Hematology Branch, National Heart Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
4Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD
Alexander J. Ambinder
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Data Availability
Raw sequencing data generated during this study has been deposited in the NCBI Sequence Reads Archive (PRJNA998386).
Posted August 21, 2023.
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
Niveditha Ravindra, Laura W. Dillon, Gege Gui, Matthew Smith, Lukasz P. Gondek, Richard J. Jones, Adam Corner, Christopher S. Hourigan, Alexander J. Ambinder
medRxiv 2023.08.14.23294087; doi: https://doi.org/10.1101/2023.08.14.23294087
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
Niveditha Ravindra, Laura W. Dillon, Gege Gui, Matthew Smith, Lukasz P. Gondek, Richard J. Jones, Adam Corner, Christopher S. Hourigan, Alexander J. Ambinder
medRxiv 2023.08.14.23294087; doi: https://doi.org/10.1101/2023.08.14.23294087
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)